Both antibodies are immunomodulators targeting the PD-1/PD-L1 pathway; approved for subsets of patients with advanced pancreatic cancer that has DNA mismatch repair deficiency (dMMR), and those with high microsatellite instability (MSI-H), DNA mismatch repair deficiency (dMMR), or high tumor mutational burden (TMB-H) (67). This evidence concerns the gene CD274 and neoplasm.